Australia markets closed

Newron Pharmaceuticals S.p.A. (0QOI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
6.83-1.03 (-13.10%)
As of 05:24PM BST. Market open.
Currency in CHF

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 337.81%
S&P500 52-week change 321.23%
52-week high 310.40
52-week low 30.00
50-day moving average 37.53
200-day moving average 35.82

Share statistics

Avg vol (3-month) 34.22k
Avg vol (10-day) 32.29k
Shares outstanding 517.84M
Implied shares outstanding 6N/A
Float 816.98M
% held by insiders 17.91%
% held by institutions 111.98%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in EUR.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -179.13%
Operating margin (ttm)-205.53%

Management effectiveness

Return on assets (ttm)-23.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)9.06M
Revenue per share (ttm)0.51
Quarterly revenue growth (yoy)9.20%
Gross profit (ttm)N/A
EBITDA -11.49M
Net income avi to common (ttm)-16.22M
Diluted EPS (ttm)-0.85
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.6M
Total cash per share (mrq)0.71
Total debt (mrq)48.41M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.68
Book value per share (mrq)-1.68

Cash flow statement

Operating cash flow (ttm)-10.14M
Levered free cash flow (ttm)-9.22M